Novel high molecular weight albumin-conjugated angiotensin II activates β-arrestin and G-protein pathways
To study the ability of a novel bovine serum albumin-angiotensin II (BSA-Ang II) conjugate to effect responses of the AT1 angiotensin II receptor subtype mediated by the G-protein-coupled and the beta-arrestin pathways.
Angiotensin II (Ang II) was conjugated with bovine serum albumin and compared with Ang II for competition binding to AT1 receptors, to stimulate aldosterone release from adrenocortical cells, to promote beta-arrestin binding to AT1 receptors, to promote calcium mobilization, and stimulate drinking of water and saline by rats.
The BSA-Ang II conjugate was less potent competing for AT1R binding, but was equally efficacious at stimulating aldosterone release from H295R adrenocortical cells. Both BSA-Ang II and Ang II stimulated calcium mobilization and beta-arrestin binding to AT1 receptors. BSA-Ang II and Ang II stimulated water appetite equivalently but BSA-Ang II stimulated saline appetite more than Ang II. Both BSA-Ang II and Ang II were considerably more potent at causing calcium mobilization than β-arrestin binding.
Addition of a high molecular weight molecule to Ang II reduced its AT1 receptor binding affinity, but did not significantly alter stimulation of aldosterone release or water consumption. The BSA-Ang II conjugate caused a greater saline appetite than Ang II suggesting that it may be a more efficacious agonist of this beta-arrestin-mediated response than Ang II. The higher potency calcium signaling response suggests that the G-protein-coupled responses predominate at physiological concentrations of Ang II, while the beta-arrestin response requires pathophysiological or pharmacological concentrations of Ang II to occur.
KeywordsAT1 receptor Biased agonism Bovine serum albumin-conjugated angiotensin II Calcium mobilization Aldosterone release Salt appetite
- Ang II
angiotensin receptor blockers;
angiotensin II receptor subtype 1;
angiotensin II receptor subtype 2;
- BSA-Ang II
Ang II conjugated to bovine albumin;
guanine nucleotide binding protein;
mitogen-activated protein kinase;
- SI Ang II
Sarcosine1 Isoleucine8 angiotensin II;
- SII Ang II
Sarcosine1 Isoleucine4 Isoleucine8 angiotensin II;
The authors thank Dr. Anastasios Lymperopoulos for assistance in experimental design and Dr. Douglas Lappi and Denise Higgins for editorial suggestions. This study was funded by a President’s Faculty Research Development Grant from Nova Southeastern University and the Cardiovascular Neuroscience Fund, Nova Southeastern University and NIH, HL-113905.
Participated in research design: H.W.P., A.L., L.C., J.S., D.D., and R.C.S.; Conducted experiments and performed data analysis: H.W.P., A.L., L.C., J.S., L.A., D.D., and R.C.S.; Wrote or contributed to the writing of the manuscript: H.W.P., J.S., L.A., D.D., and R.C.S.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.S.D. Crowley, S.B. Gurley, M.I. Oliverio, A.K. Pazmino, R. Griffiths, P.J. Flannery, R.F. Spurney, H.S. Kim, O. Smithies, T.H. Le, T.M. Coffman, Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J. Clin. Invest. 115(4), 1092–1099 (2005)CrossRefGoogle Scholar
- 2.S.S. Karnik, H. Unal, J.R. Kemp, K.C. Tirupula, S. Eguchi, P.M. Vanderheyden, W.G. Thomas, International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli. Pharmacol. Rev. 67(4), 754–819 (2015). https://doi.org/10.1124/pr.114.010454 CrossRefGoogle Scholar
- 6.D.A. Booth, Mechanism of action of norepinephrine in eliciting an eating response on injection into the rat hypothalamus. J. Pharmacol. Exp. Ther. 160(2), 336–348 (1968)Google Scholar
- 7.J.T. Fitzsimons, E.M. Stricker, Sodium appetite and the renin-angiotensin system. Nat.: New Biol. 231(19), 58–60 (1971)Google Scholar
- 8.J.T. Fitzsimons, Angiotensin, thirst, and sodium appetite: retrospect and prospect. Fed. Proc. 37(13), 2669–2675 (1978)Google Scholar
- 13.L.M. Luttrell, F.L. Roudabush, E.W. Choy, W.E. Miller, M.E. Field, K.L. Pierce, R.J. Lefkowitz, Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc. Natl Acad. Sci. USA 98(5), 2449–2454 (2001). https://doi.org/10.1073/pnas.041604898
- 14.Kohout, T. A., Lin, F. S., Perry, S. J., Conner, D. A., Lefkowitz, R. J.: beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc. Natl Acad. Sci. USA 98(4), 1601–1606 (2001). https://doi.org/10.1073/pnas.041608198
- 15.R.H. Oakley, S.A. Laporte, J.A. Holt, M.G. Caron, L.S. Barak, Differential affinities of visual arrestin, betaarrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J. Biol. Chem. 275(22), 17201–17210 (2000). https://doi.org/10.1074/jbc.M910348199 CrossRefGoogle Scholar
- 17.M.M. Monasky, D.M. Taglieri, M. Henze, C.M. Warren, M.S. Utter, D.G. Soergel, J.D. Violin, R.J. Solaro, The beta-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium. Am. J. Physiol. Heart Circ. Physiol. 305(6), H856–866 (2013). https://doi.org/10.1152/ajpheart.00327.2013 CrossRefGoogle Scholar
- 18.D.G. Romero, M.Y. Zhou, L.L. Yanes, M.W. Plonczynski, T.R. Washington, C.E. Gomez-Sanchez, E.P. Gomez-Sanchez, Regulators of G-protein signaling 4 in adrenal gland: localization, regulation, and role in aldosterone secretion. J. Endocrinol. 194(2), 429–440 (2007). https://doi.org/10.1677/joe-07-0153 CrossRefGoogle Scholar
- 19.A. Lymperopoulos, G. Rengo, C. Zincarelli, J. Kim, S. Soltys, W.J. Koch, An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc. Natl Acad. Sci. USA 106(14), 5825–5830 (2009). https://doi.org/10.1073/pnas.0811706106
- 21.A.C. Holloway, H. Qian, L. Pipolo, J. Ziogas, S. Miura, S. Karnik, B.R. Southwell, M.J. Lew, W.G. Thomas, Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol. Pharmacol. 61(4), 768–777 (2002)CrossRefGoogle Scholar
- 22.J.D. Violin, S.M. DeWire, D. Yamashita, D.H. Rominger, L. Nguyen, K. Schiller, E.J. Whalen, M. Gowen, M.W. Lark, Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J. Pharmacol. Exp. Ther. 335(3), 572–579 (2010). https://doi.org/10.1124/jpet.110.173005 CrossRefGoogle Scholar
- 26.J. Liu, G.L. Yosten, H. Ji, D. Zhang, W. Zheng, R. C. Speth, W. K. Samson, K. Sandberg, Selective inhibition of angiotensin receptor signaling through Erk1/2 pathway by a novel peptide. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2014). https://doi.org/10.1152/ajpregu.00562.2013
- 27.D. Torres-Tirado, J. Ramiro-Diaz, M.T. Knabb, R. Rubio, Molecular weight of different angiotensin II polymers directly determines: density of endothelial membrane AT1 receptors and coronary vasoconstriction. Vasc. Pharmacol. 58(5-6), 346–355 (2013). https://doi.org/10.1016/j.vph.2013.03.002 CrossRefGoogle Scholar
- 34.J. Castillo-Hernandez, D. Torres-Tirado, A. Barajas-Espinosa, E. Chi-Ahumada, J. Ramiro-Diaz, G. Ceballos, R. Rubio, Two dissimilar AT(1) agonists distinctively activate AT(1) receptors located on the luminal membrane of coronary endothelium. Vasc. Pharmacol. 51(5-6), 314–322 (2009). https://doi.org/10.1016/j.vph.2009.07.003 CrossRefGoogle Scholar
- 35.I.M. Bird, N.A. Hanley, R.A. Word, J.M. Mathis, J.L. McCarthy, J.I. Mason, W.E. Rainey, Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II-responsive aldosterone secretion. Endocrinology 133(4), 1555–1561 (1993). https://doi.org/10.1210/endo.133.4.8404594 CrossRefGoogle Scholar
- 37.T. Inagami, S. Eguchi, K. Numaguchi, E.D. Motley, H. Tang, T. Matsumoto, T. Yamakawa, Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases. J. Am. Soc. Nephrol.: JASN 10(Suppl 11), S57–61 (1999)Google Scholar
- 41.G. Mariani, S. Ito, R.C. Nayak, J. Baranowska-Kortylewicz, C.N. Venkateshan, A.D. Van den Abbeele, G.S. Eisenbarth, S.J. Adelstein, A.I: Kassis, Capping and internalization of a monoclonal antibody-surface antigen complex: a possible mode of interaction of monoclonal antibodies and tumor cells. J. Nucl. Biol. Med. (Turin, Italy.: 1991) 35(2), 111–119 (1991)Google Scholar
- 42.O. Behnke, Surface membrane clearing of receptor-ligand complexes in human blood platelets. J. cell Sci. 87(Pt 3), 465–472 (1987)Google Scholar